In contrast, a recent study from Jeong et al. demonstrated that deletion of KEAP1 conferred chemoresistance in preclinical models of lung adenocarcinoma and that patients with late stage NSCLC with KEAP1/NFE2L2/CUL3 mutations had a shorter time to treatment failure and overall survival when treated with front-line platinum doublet chemotherapy [121]. Here, NFE2L2 is linked to lung adenocarcinoma.